Status:
UNKNOWN
Prolaris Enhanced Risk Stratification - an ecONomic and clinicAL Evaluation
Lead Sponsor:
The Leeds Teaching Hospitals NHS Trust
Conditions:
Prostate Cancer
Eligibility:
MALE
18-100 years
Brief Summary
One in 8 men will be diagnosed with prostate cancer during their lifetime. The majority of men diagnosed with prostate cancer have early stage disease, which can be managed in a variety of ways, rangi...
Eligibility Criteria
Inclusion
- Clinical suspicion of prostate cancer
- Able to provide informed written consent
- No contraindication to prostate biopsy
- Newly diagnosed treatment-naive patient with histologically proven localised adenocarcinoma of the prostate
- Low or intermediate D'Amico risk prostate cancer
- Sufficient quantity and quality of tissue remains from biopsy to perform genomic testing
- No contraindication to radical treatment if diagnosed with localised prostate cancer
- Estimated life expectancy \>10 years
Exclusion
- Men with locally advanced, clinical node positive or metastatic disease
- Patients who lack capacity to consent to study participation
- Non-adenocarcinoma prostate cancer histology
Key Trial Info
Start Date :
February 21 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 30 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03851211
Start Date
February 21 2019
End Date
October 30 2020
Last Update
February 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St James's University Hospitals NHS Trust
Leeds, West Yorkshire, United Kingdom, LS9 7TF